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BACKGROUND: In the Phase 3 REFLECT trial in patients with unresectable hepatocellular carcinoma (uHCC), the multitargeted
tyrosine kinase inhibitor, lenvatinib, was noninferior to sorafenib in the primary outcome of overall survival. Post-hoc review
revealed imbalances in prognostic variables between treatment arms. Here, we re-analyse overall survival data from REFLECT to
adjust for the imbalance in covariates.
METHODS: Univariable and multivariable adjustments were undertaken for a candidate set of covariate values that a physician
panel indicated could be prognostically associated with overall survival in uHCC. The values included baseline variables observed
pre- and post-randomisation. Univariable analyses were based on a stratified Cox model. The multivariable analysis used a
“forwards stepwise” Cox model.
RESULTS: Univariable analysis identified alpha-fetoprotein (AFP) as the most influential variable. The chosen multivariable Cox
model analysis resulted in an estimated adjusted hazard ratio for lenvatinib of 0.814 (95% CI: 0.699–0.948) when only baseline
variables were included. Adjusting for post-randomisation treatment variables further increased the estimated superiority of
lenvatinib.
CONCLUSIONS: Covariate adjustment of REFLECT suggests that the original noninferiority trial likely underestimated the true effect
of lenvatinib on overall survival due to an imbalance in baseline prognostic covariates and the greater use of post-treatment
therapies in the sorafenib arm.
TRIAL REGISTRATION: Trial number: NCT01761266 (Submitted January 2, 2013).
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BACKGROUND
In a Phase 3 trial (REFLECT) in patients with unresectable
hepatocellular carcinoma (uHCC), the multitargeted tyrosine
kinase inhibitor, lenvatinib, was shown to be noninferior to
the standard-of-care treatment, sorafenib, in terms of the primary
outcome of overall survival.1 The study reported that the median
overall survival was longer for lenvatinib (13.6 months) compared
to 12.3 months for sorafenib, but this difference was not
statistically significant. The hazard ratio from a stratified Cox
proportional hazards model was 0.92 with a 95% confidence
interval (CI) of 0.79 to 1.06. Lenvatinib passed the noninferiority
test that the upper CI of the hazard ratio for overall survival should
be no greater than 1.08.1
Although superiority for lenvatinib in terms of overall survival
cannot be shown based on the primary efficacy analysis, there are a
number of reasons why lenvatinib may be superior to the standard-
of-care treatment, sorafenib. First, the superiority of lenvatinib based
on secondary end points of progression-free survival, with a
reported hazard ratio in the Phase 3 trial of 0.66 (95% CI:
0.57–0.77), and objective response rate, with a reported odds ratio
of 3.13 (95% CI: 2.15–4.56). Second, an imbalance in the baseline
prognostic factors appeared to bias the outcomes against lenvatinib.
Finally, there was a greater number of post-treatment therapies used
after sorafenib compared with lenvatinib, leading the authors of the
original study to speculate that: “If post-progression survival is
prolonged by…post-study treatments, this could lead to a dilution
of the observed overall survival treatment benefit”.1
The aim of this manuscript is to assess an alternative analysis of
the overall survival data from REFLECT to identify and adjust for
the imbalance in covariates.
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METHODS
REFLECT was a multicentre, randomised, open-label, noninferior-
ity, phase 3 study that compared the efficacy and safety of
lenvatinib vs. sorafenib as a first-line systemic treatment in
patients with uHCC.1 Patients were randomly assigned in a 1:1
ratio to treatment with either lenvatinib 12mg (if baseline
bodyweight was ≥60 kg) or 8 mg (if baseline bodyweight was
<60 kg) given once daily orally, or sorafenib 400 mg given twice
daily orally. Patients were stratified by: geographical region;
presence of macroscopic portal vein invasion (MPVI), extrahepatic
spread (EHS) or both; Eastern Cooperative Oncology Group
performance status (ECOG PS) 0 or 1; and bodyweight (<60 kg
or ≥60 kg).1 No crossover to lenvatinib from the sorafenib arm was
allowed.
The choice of covariates to consider as candidate variables in
this analysis was informed by discussion among the clinical
authors of the manuscript, who formed the purposive expert
sample.2 Each clinician was asked to comment on the likely
prognostic importance of the baseline patient characteristics from
the original clinical trial,1 and all covariates that were considered
as potentially important by any of the clinical experts were used in
the initial determination of which variables to include in a model
for overall survival.
To determine the potential importance of the candidate
variables identified by the clinical experts, each variable was
entered into the Cox proportional hazards regression model as a
univariate adjustment of the treatment effect. This univariate
analysis retained the original stratification variables of: geogra-
phical region; presence or absence of MPVI, EHS or both; ECOG PS
and bodyweight.
A multivariable adjusted analysis was then developed using a
forward stepwise procedure from the candidate variables
identified by clinicians. In this case, “forwards stepwise” indicates
that the procedure starts from a model with treatment effect as
the only covariate and systematically considers each candidate
variable for inclusion. Candidate covariates were included in
further analysis if the p-value was <0.05. As variables are added,
individual p-values for variables in the model can change—in
addition to selecting additional variables for inclusion to the
model, the stepwise procedure also drops existing variables from
the model if the p-value becomes >0.1. In the multivariable
analysis, the original stratification variables were included as
potential covariates, but were not retained as stratification
variables.
Sensitivity analyses were conducted on a number of aspects of
the analysis: the default Wald test for the standard stepwise
procedure was replaced by the Likelihood Ratio (LR) test; variable
selection was also tested using the Akaike information criterion
(AIC),3 which further penalises the likelihood for the number of
parameters in the model; and backwards selection (where the
model starts with all candidate variables) was contrasted with the
forwards selection procedure for determining variable selection. In
addition, post-treatment variables were included in the analysis to
adjust for the potential dilution effect of the imbalance in post-
progression therapies between the two treatment arms (i.e. post-
randomisation confounding).
All statistical analyses were undertaken in STATA™ version 14.4
RESULTS
The baseline characteristics for REFLECT, which were considered
by the clinical authors to have potential prognostic importance,
are presented in Table 1 for the sorafenib and lenvatinib treatment
groups. Age and sex are also included for information, although it
should be noted that these demographic factors were not
considered to impact disease prognosis by the authors. Geogra-
phical region (Western vs. Asia-Pacific), MPVI or EHS or both, ECOG
PS (0 or 1), and bodyweight (<60 kg or ≥60 kg) were stratification
variables in the original clinical trial. Table 1 shows these variables
were balanced across the study arms. Some of the non-
stratification covariates show potential imbalance: in particular,
AFP is known to correlate with prognosis1,5 and here the
imbalance suggests that the sorafenib arm, with a greater
proportion of patients having AFP < 200 ng/ml level, may have
included patients with disease who showed better prognosis.6,7
There is also evidence that suggests that the effect of sorafenib on
overall survival is dependent on patients’ hepatitis status with a
greater improvement in survival for sorafenib-treated patients
positive for HCV compared to patients positive for HBV, in which
sorafenib is less active.7 Also included in Table 1 are three post-
treatment variables reflecting anti-cancer treatment therapies
received post-treatment with either lenvatinib or sorafenib. The
post-treatment therapy variable includes both post-treatment
anti-cancer procedures (e.g. radiotherapy) and/or post-treatment
anti-cancer medications.
The Forest plot in Fig. 1 shows the univariable impact on the
estimated hazard ratio for lenvatinib treatment compared to
sorafenib after adjusting for each covariate in Table 1. In terms of
these univariable results, MPVI or EHS or both, AFP < 200 ng/mL,
disease site, hepatitis B aetiology, and receipt of a previous
procedure are all predictive of overall survival and adjusting for
them influences the estimated hazard ratio of the treatment effect
in favour of lenvatinib. The Child-Pugh score is also predictive for
overall survival, but adjustment favours sorafenib. Finally, adjust-
ments for the imbalance in the post-treatment covariates also
have a strong impact on the treatment hazard ratio in favour of
lenvatinib. Overall, it is clear from the univariable analysis that AFP
level has the single greatest impact on the estimated hazard ratio
for overall survival. Indeed, adjusting for AFP alone generates a
significant treatment effect in favour of lenvatinib at conventional
statistical significance levels with an estimated overall survival
hazard of 0.856 with 95% CI ranging from 0.736 to 0.995.
A parsimonious multivariable model is reported in Table 2 using
a forward stepwise procedure. Model 1 is the standard model that
employs a Wald test for significance. Model 2 represents a
sensitivity analysis where the LR test is used instead of the Wald
test. As can be seen in Table 2, the final variable selection is
identical. In the final column in Table 2, the AIC analysis shows
that each successive covariate included in the model further
reduces the AIC (i.e. all covariates contribute to the model even
when penalising for the use of additional parameters). The
confluence of these approaches suggests a strong basis for the
multivariable adjusted hazard ratio for lenvatinib overall survival
of 0.814 (95% CI: 0.699–0.948).
A sensitivity analysis is shown in Table 3 for including post-
treatment variables into the model. Model 1 includes the
composite post-treatment “therapy” variable and Model 2 shows
this split out as post-treatment procedures and post-treatment
medications. Both models show that the post-treatment anti-
cancer variables are highly significant predictors of outcome. In
addition, adjusting for these post-randomisation imbalances
impacts the hazard ratio of the treatment arms. Comparing the
AIC scores for non-nested models shows support for Model 2
compared with Model 1 despite the additional parameter. This
gives an adjusted hazard ratio for lenvatinib overall survival of
0.765 (95% CI: 0.656–0.892).
As an additional sensitivity analysis, the forwards stepwise
procedure was repeated as a backwards procedure (Table 4). Here,
Model 1 relates to baseline variables only and Model 2 includes
post-treatment variables. The backwards selection procedure
identifies slightly different adjustment variables than the forward
selection process, but the main effects of the model are similar
with an adjusted hazard ratio for lenvatinib of 0.814 (95% CI:
0.699–0.948). Similarly, the addition of post-treatment procedure
and medication variables gives a virtually identical hazard ratio to
the forward selection model: 0.765 (95% CI: 0.656–0.892).
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DISCUSSION
This study has reanalysed the REFLECT noninferiority study that
compared lenvatinib and sorafenib for the treatment of uHCC in a
multivariable modelling framework. The initial study’s strong
positive result in favour of lenvatinib for the secondary end points
of progression-free survival and objective response rate, the
imbalance of baseline covariates favouring sorafenib, and the
greater use of subsequent anti-cancer therapies after progression
in the sorafenib arm, all suggested that lenvatinib could be
superior to sorafenib in terms of overall survival. Our covariate-
adjusted results indicate that lenvatinib treatment of uHCC may
reach superiority for overall survival vs. sorafenib at conventional
levels of statistical significance once baseline imbalances in
important prognostic variables are controlled for. This effect is
magnified when further adjustment is made for post-treatment
therapy variables.
However, we remain cautious when it comes to interpretation
of this analysis. This is a post-hoc analysis and cannot change the
results of the original trial, though it allows us to better
understand them. In particular, adjusting for post-treatment
variables violates the randomisation principle and could, itself,
lead to bias. More sophisticated techniques and further post-
randomisation data on the reasons for receiving the different
post-progression therapies would be needed to perform a full
causal analysis, adjusting for imbalances in line therapies.8,9
By contrast, the use of covariate analysis in randomised
controlled studies is far less contentious. Although not permitted
in regulatory analyses designed to support licensing applications,
the use of covariate adjustment is recommended by leading
Table 1. Patient demographics and baseline characteristics.
Characteristic, n Sorafenib (n= 476) Lenvatinib (n= 478)
Age, years
<60 283 270
60–75 126 150
>75 67 58
Sex
Male 401 405
Female 75 73
Regiona
Western 157 157
Asia-Pacific 319 321
Macroscopic portal vein invasion (MPVI)
Yes 90 109
No 386 369
Extrahepatic spread (EHS)
Yes 295 291
No 181 187
MPVI, EHS, or botha
Yes 336 329
No 140 149
ECOG Performance statusa
0 301 304
1+ 175 174
Bodyweight group, kga
<60 146 153
≥60 330 325
Alpha fetoprotein, ng/ml
<200 286 255
≥200 187 222
Missing 3 1
Child-Pugh score
5 357 368
6+ 119 110
Number of disease sites
1 207 207
2 183 167
≥3 86 103
Etiology
HBV 228 251
HCV 126 91
Alcohol 21 36
Other 32 38
Unknown 69 62
Underlying cirrhosis
Yes 231 243
No 245 235
BCLC Staging
Stage B 92 104
Stage C 384 374
Prior procedure
Yes 344 327
No 132 151
Liver disease site
Not involved 46 37
Table 1 continued
Characteristic, n Sorafenib (n= 476) Lenvatinib (n= 478)
Involved 430 441
Lung disease site
Not involved 332 315
Involved 144 163
Bone disease site
Not involved 433 427
Involved 43 51
Lymph node disease site
Not involved 335 351
Involved 141 127
Other disease site
Not Involved 379 396
Involved 97 82
Post-treatment therapyb,c
Yes 243 206
No 233 272
Post-treatment procedureb
Yes 112 99
No 364 379
Post-treatment medicationb
Yes 184 156
No 292 322
BCLC Barcelona Clinic Liver Cancer, ECOG PS Eastern Cooperative Oncology
Group performance status, HBV hepatitis B virus, HCV hepatitis C virus.
aStratification variables in the original Statistical Analysis Plan.
bPost-trandomisation variables.
cPost-treatment therapy= post-treatment procedure and/or post-
treatment medication.
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medical statisticians.10,11 This is because covariate adjustment can
improve the analysis both in terms of correcting for the potential
bias of imbalance in prognostic variables and also in terms of
increasing the precision of estimated treatment effects. The latter
effect occurs even when there is no imbalance if important
prognostic variables are available because the multivariable model
uses the covariate information to explain some of the “noise” in
the data, increasing the precision of all estimated quantities. Note
that it is the strength of the prognostic power of the imbalanced
variable, rather than the statistical significance of the imbalance
that is the issue. Leading medical journals, including The Lancet,
where the original clinical trial was published,1 discourage the use
of p-values to compare the balance of the randomised groups.
Assuming appropriate randomisation, any observed imbalance
occurs by chance and so arbitrary p-values are not required to
make this judgement. Further, it is the prognostic importance of a
given variable that determines the importance of any imbalance.
This is illustrated in the analysis presented here by noting that
adjusting for the imbalance of AFP level had the greatest single
effect on the estimated hazard ratio for lenvatinib treatment.
However, statistical testing of the imbalance results in a marginally
insignificant difference between the groups in Table 1 (p-values
not reported).
Indeed, a recent issue of The American Statistician is heralding
the end of the p-value and significance testing.12 While this may
be premature for appropriately conducted, randomised, con-
trolled trials designed to test a specific hypothesis, the principles
do apply to secondary analyses such as presented in this
Age
Sex
Region
MPVI
EHS
MPVI or EHS or both
ECOG PS
Baseline weight
Alpha fetoprotein >200 ng/mL
Child Pugh score
Number of disease sites
Entiology
Cirrhosis
BCLC stage
Liver disease
Lung disease
Bone disease
Lymph disease
Other disease
Previous procedure
Post treatment therapy
Post treatment procedure
Post treatment medication
0.7 0.8 0.9
Hazard ratio
Increasing lenvatinib effect Increasing sorafenib effect
Unadjusted treatment
effect estimate
1 1.1 1.2 1.3
Fig. 1 Forest plot of univariate impact of candidate covariates on lenvatinib treatment effect. BCLC Barcelona Clinic Liver Cancer, ECOG PS
Eastern Cooperative Oncology Group Performance Status, EHS extrahepatic spread, HBV hepatitis B virus, HCV hepatitis C virus, MPVI
macroscopic portal vein invasion.
Table 2. Forwards stepwise selection modela.
Parameter Model 1 Model 2 AIC
HR p-value 95% CI HR p-value 95% CI
Lenvatinib 0.814 0.008 0.699 0.948 0.814 0.008 0.699 0.948 8678
Alpha fetoprotein >200 ng/ml 1.725 <0.001 1.478 2.014 1.725 <0.001 1.478 2.014 8603
Child-Pugh Score 1.676 <0.001 1.411 1.992 1.676 <0.001 1.411 1.992 8573
EHS 1.248 0.039 1.011 1.540 1.248 0.039 1.011 1.540 8551
Liver disease involvement 2.345 <0.001 1.676 3.282 2.345 <0.001 1.676 3.282 8518
MPVI 1.351 0.001 1.129 1.617 1.351 0.001 1.129 1.617 8510
Hepatitis B 1.231 0.008 1.057 1.433 1.231 0.008 1.057 1.433 8504
Bone disease involvement 1.510 0.001 1.181 1.932 1.510 0.001 1.181 1.932 8499
Lung disease involvement 1.319 0.005 1.085 1.603 1.319 0.005 1.085 1.603 8496
Other disease involvement 1.289 0.014 1.052 1.579 1.289 0.014 1.052 1.579 8492
P < 0.05 required for covariate inclusion, P < 0.1 required for covariate deletion. Model 1 uses the Wald test for inclusion/deletion; Model 2 uses the likelihood
ratio test.
AIC Akaike information criterion, EHS extrahepatic spread, HR hazard ratio for overall survival, MVPI macroscopic portal vein invasion.
aForwards stepwise selection model starting from model with treatment alone.
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manuscript. For this reason, we focus throughout on the
estimated treatment effect with accompanying CIs.
CONCLUSIONS
Covariate adjustment of the REFLECT data strongly suggests that the
original noninferiority trial likely underestimated the true effect of
lenvatinib on overall survival due to imbalances in baseline
prognostic covariates (in particular, AFP level) and the comparatively
greater use of post-treatment anti-cancer therapies in the sorafenib
arm. While the scale of the impact of covariate adjustment on
treatment effect varies, the analyses reported here all favoured
lenvatinib. Considering the potential biases associated with
adjusting for post-randomisation variables, the preferred base-case
hazard ratio is that based on adjusting for baseline covariates only.
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Table 3. Sensitivity analysis results adding post-trandomisation covariates.
Parameter Model 1 Model 2
HR p-value 95% CI HR p-value 95% CI
Lenvatinib 0.760 <0.001 0.652 0.887 0.765 0.001 0.656 0.892
Alpha fetoprotein >200 ng/ml 1.696 <0.001 1.453 1.980 1.685 <0.001 1.443 1.968
Child-Pugh Score 1.590 <0.001 1.338 1.890 1.579 <0.001 1.328 1.878
EHS 1.248 0.038 1.013 1.538 1.258 0.031 1.021 1.549
Liver disease involvement 2.371 <0.001 1.693 3.319 2.369 <0.001 1.692 3.317
MPVI 1.299 0.004 1.085 1.556 1.309 0.003 1.094 1.567
Hepatitis B 1.222 0.010 1.049 1.422 1.219 0.011 1.047 1.419
Bone disease involvement 1.561 <0.001 1.220 1.997 1.541 0.001 1.205 1.970
Lung disease involvement 1.358 0.002 1.118 1.649 1.358 0.002 1.119 1.649
Other disease involvement 1.229 0.045 1.005 1.504 1.204 0.071 0.984 1.474
Post-treatment therapy 0.599 <0.001 0.514 0.699 – – – –
Post-treatment medication – – – – 0.681 <0.001 0.579 0.802
Post-treatment procedure – – – – 0.690 <0.001 0.569 0.835
AIC 8402 8400
AIC Akaike information criterion, EHS extrahepatic spread, HR hazard ratio for overall survival, MVPI macroscopic portal vein invasion.
Table 4. Sensitivity analysis using backwards selection.
Model 1a Model 2b Model 3c
HR p-value 95% CI HR p-value 95% CI HR p-value 95% CI
Lenvatinib 0.814 0.008 0.699 0.948 0.765 0.001 0.656 0.892 0.760 <0.001 0.652 0.887
Alpha Fetoprotein >200 ng/mL 1.725 <0.001 1.478 2.014 1.685 <0.001 1.443 1.968 1.696 <0.001 1.453 1.980
Child-Pugh Score 1.676 <0.001 1.411 1.992 1.579 <0.001 1.328 1.878 1.590 <0.001 1.338 1.890
EHS 1.248 0.039 1.011 1.540 1.258 0.031 1.021 1.549 1.248 0.038 1.013 1.538
Liver Disease Involvement 2.345 <0.001 1.676 3.282 2.369 <0.001 1.692 3.317 2.371 <0.001 1.693 3.319
MPVI 1.351 0.001 1.129 1.617 1.309 0.003 1.094 1.567 1.299 0.004 1.085 1.556
Hepatitis B 1.231 0.008 1.057 1.433 1.219 0.011 1.047 1.419 1.222 0.010 1.049 1.422
Bone Disease Involvement 1.510 0.001 1.181 1.932 1.541 0.001 1.205 1.970 1.561 <0.001 1.220 1.997
Lung Disease Involvement 1.319 0.005 1.085 1.603 1.358 0.002 1.119 1.649 1.358 0.002 1.118 1.649
Other Disease Involvement 1.289 0.014 1.052 1.579 1.204 0.071 0.984 1.474 1.229 0.045 1.005 1.504
Post-treatment Therapy – – – – – – – – 0.599 <0.001 0.514 0.699
Post-treatment Medication – – – – 0.681 <0.001 0.579 0.802 – – – –
Post-treatment Procedure – – – – 0.690 <0.001 0.569 0.835 – – – –
AIC 8443 8400 8402
MVPI Macroscopic Portal Vein Invasion, EHS Extra-Hepatic Spread, AIC Aikake’s Information Criterion.
aBackwards selection model starting from full multivariable model. Pr(0.05) required for covariate deletion.
bBaseline covariates as Model 1 + post-treatment covariates separately.
cBaseline covariates as Model 1 + post-treatment covariates as a composite variable.
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib. . .
A Briggs et al.
1758
ADDITIONAL INFORMATION
Ethics approval and consent to participate This is a reanalysis of existing data from
the REFLECT study. All patients provided written informed consent to participate in
the study as detailed in the original clinical trial manuscript (Kudo 2018). This study
was conducted in accordance with the Declaration of Helsinki.
Consent to publish No individual person’s data are used in this manuscript in any
form, so no consent for publication was required.
Data availability Data are held by the sponsors: Eisai Inc., and Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., to whom all requests for data access should be
addressed.
Competing interests Sponsorship for the study and analysis were funded by Eisai Inc.,
and Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co., Inc., and study
results were not contingent on the sponsors’ approvals nor did they conduct any
censorship of the manuscript. A.B. is a director and shareholder of Avalon Health
Economics and received compensation from Eisai as a consultant for this work. He has
also been contracted by Bayer, Merck, Janssen, Novartis, Sword Health, Amgen, and
Daichii Sankyo and received compensation outside of the submitted work. B.D. reports
no conflicts of interest regarding the work at hand but has received personal fees and
non-financial support for consultation for Ispen, Sanofi, and Bayer, and personal fees
from Eisai, Eli Lilly, Astra Zeneca, and Incyte outside of the submitted work. K.D. is an
employee of Avalon Health Economics. T.R.J.E. has received honoraria for advisory
boards and/or speaker’s fees from Eisai, Celgene, Bristol-Myers Squibb, Bayer, Roche,
Merck (MSD), Nucana, Karus Therapeutics, Modulate Therapeutics (all payable to the
employing institution), research funding for clinical trials from multiple pharmaceutical
and biotechnology companies including Eisai (all payable to the employing institution),
and support to attend international scientific conferences from Bristol-Myers Squibb,
Merck, Eisai, Bayer, Roche, Pierre Fabre, and Celgene. He is co-editor of the clinical study
section of the British Journal of Cancer (honorarium payable to the employing
institution). P.R.G. has received compensation from Eisai for this work and for adboards
and lectures from Bayer, AstraZeneca, BMS, MSD, Roche, Sirtex, Ispen, and Lilly outside
of the submitted work. R.A.H. received consultancy fees from Eisai for this work. He has
also received compensation from Roche and Ispen and attended conferences for both
Roche and BMS outside of the submitted work. C.L. has been paid honoraria for
consultancy on this work. He has also received compensation for work from Ispen,
Bayer, BMS, and Astra Zeneca, and has participated in a speaker’s bureau for Eisai, Ispen,
Bayer, and BMS. Further, he has received research funding from Eisai, Ispen, BMS, MSD,
Astra Zeneca, and Roche. U.S. has received honorarium for participating in an advisory
board of Eisai and reports no other conflicts of interest. G.T. reports no conflicts of
interest regarding the submitted work.
Funding information This study was funded by Eisai Inc., Woodcliff Lake, NJ, USA,
and Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co., Inc., Kenilworth,
NJ, USA.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F. et al. Lenvatinib
versus sorafenib in first-line treatment of patients with unresectable hepatocel-
lular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391,
1163–1173 (2018).
2. Etickan, I., Musa, S. A. & Alkassim, R. S. Comparison of convenience sampling and
purposive sampling. Am. J. Theor. Appl. Stat. 5, 1–4 (2016).
3. Burnham, K. P. & Anderson, D. R. Multimodel inference: understanding AIC and
BIC in model selection. Sociol. Methods Res. 33, 261–304 (2004).
4. StataCorp. Stata Statistical Software: Release 14. (StataCorp LP, College Station,
2015).
5. Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J. et al.
Metroticket 2.0 model for analysis of competing risks of death after liver
transplantation for hepatocellular carcinoma. Gastroenterology 154, 128–139
(2018).
6. Broadhurst, P., Toyoda, H., Kumada, T., Schweitzer, N., Vogel, A., Benckert, J. et al.
Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular
carcinoma: an international collaborative study. J. Hepatol. 66, S620–S621 (2017).
7. Bruix, J., Cheng, A. L., Meinhardt, G., Nakajima, K., De Sanctis, Y. & Llovet, J.
Prognostic factors and predictors of sorafenib benefit in patients with hepato-
cellular carcinoma: analysis of two phase III studies. J. Hepatol. 67, 999–1008
(2017).
8. Robins, J. M., Hernán, M., Siebert, U. Estimations of the Effects of Multiple
Interventions. In: Ezzati, M. L. A., Rodgers, A., Mrray, C. J. L., editors. Comparative
Quantification of Health Risks: Global and Regional Burden of Disease Attribu-
table to Selected Major Risk Factors. 1. p. 2191–2230 (World Health Organization,
Geneva, 2004).
9. Hernán, M. & Robins, J. M. Per-protocol analyses of pragmatic trials. N. Engl. J.
Med. 337, 1391–1398 (2017).
10. Altman, D. G. Comparability of randomised groups. J. R. Stat. Soc. Ser. D. (Statis-
tician) 34, 125–136 (1985).
11. Pocock, S. Clinical Trials: A Practical Approach (Chichester, Wiley, 1983).
12. Wasserstein, R. L., Schirm, A. L. & Lazar, N. A. Moving to a world beyond “p < 0.05”.
Am. Statistician 73(sup1), 1–19 (2019).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib. . .
A Briggs et al.
1759
